CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
Retrieved on:
화요일, 3월 26, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Human, PYY, Obesity, Neuropeptide, Appetite, Patient, Weight loss, Trial of the century, IND, Nausea, PYY3-36, Safety, Pharmacokinetics, Therapy, Vomiting, Y2R, Pharma, Food, DSM-IV codes, Pharmaceutical industry
With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.
Key Points:
- With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.
- The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in a randomized, double-blind, placebo-controlled, single ascending dose study in otherwise healthy subjects with obesity.
- PYY3-36 is an endogenous hormone secreted in the gut, which activates the neuropeptide Y2 receptor (Y2R) to reduce appetite and food intake.
- “The preclinical program of CIN-110 underscores the potential for PYY to be a differentiated approach to treat obesity.